Tekmira makes three appointments
This article was originally published in Scrip
Tekmira Pharmaceuticals, a company focused on developing treatments for chronic hepatitis B virus infection (HBV), has made three executive appointments: Adam Cutler has been appointed senior vice-president, corporate affairs; Dr Bruce Dorsey has been appointed vice-president, chemistry; and Dr Rene Cornelis Rijnbrand has been named vice-president, Biology. Mr Cutler joins Tekmira from The Trout Group and Trout Capital. Before this he spent almost 12 years as a sell-side analyst with firms including Credit Suisse, Canaccord Genuity, JMP Securities, and Banc of America Securities. Mr Dorsey was most recently vice-president of chemistry with OnCore Biopharma, focusing on HBV and building the company's US operations. Finally, Mr Rijnbrand joins Tekmira from OnCore Biopharma where he was vice-president and head of biology.